


# End Stage Renal Disease (ESRD) Drug Market Size, Share, Revenue, Trends, and Drivers For 2024-2033

*The Business Research Company's End Stage Renal Disease (ESRD) Drug Market Size, Share, Revenue, Trends, and Drivers For 2024-2033*

LONDON, GREATER LONDON, UNITED KINGDOM, October 2, 2024

/EINPresswire.com/ -- The end stage renal disease (ESRD) drug market has experienced robust growth in recent years, expanding from \$116.32 billion in 2023 to \$132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.

## End Stage Renal Disease (ESRD) Drug Global Market Report 2024



End Stage Renal Disease (ESRD) Drug Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

What Is The Estimated Market Size Of The Global End Stage Renal Disease (ESRD) Drug Market And Its Annual Growth Rate?



It will grow to \$232.13 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%.”

*The Business Research Company*

The end stage renal disease (ESRD) drug market is projected to continue its strong growth, reaching \$232.13 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals.

Explore Comprehensive Insights Into The Global End Stage Renal Disease (ESRD) Drug Market With A Detailed Sample Report:

[https://www.thebusinessresearchcompany.com/sample\\_request?id=9437&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=9437&type=smp)

Growth Driver Of The End Stage Renal Disease (ESRD) Drug Market

Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control.

Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:

<https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report>

Who Are The Leading Competitors In The End Stage Renal Disease (ESRD) Drug Market Share?

Key players in the market include Pfizer Inc., AstraZeneca PLC, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. Kagan, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Cantel Medical Corp., Nikkiso Co. Ltd., Abbott Laboratories, Alere Inc., Siemens Healthcare AG, Roche Diagnostics Corporation, Beckman Coulter Inc., Becton Dickinson And Co., Thermo Fisher Scientific Inc., BioMerieux SA, Bio-Rad Laboratories, Randox Laboratories, Enzo Biochem Inc., Merck Co. & KGaA, QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH.

What Are The Dominant Trends In End Stage Renal Disease (ESRD) Drug Market Growth?

Major companies operating in the end-stage renal disease (ESRD) drug market are focusing on product approvals such as Jardiance to drive revenues in their market. Empagliflozin is a drug intended to help persons with type 2 diabetes and to lower the chance of cardiovascular issues in persons with type 2 diabetes who have heart failure or cardiovascular disease.

How Is The Global End Stage Renal Disease (ESRD) Drug Market Segmented?

- 1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
- 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalemia
- 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
- 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Geographical Insights: North America Leading The End Stage Renal Disease (ESRD) Drug Market  
North America was the largest region in the market in 2023. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#### End Stage Renal Disease (ESRD) Drug Market Definition

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person's kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

End Stage Renal Disease (ESRD) Drug Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Macroeconomic factors affecting the market in the short and long run
- Analysis of the macro and micro economic factors that have affected the market in the past five years
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

An overview of the global end stage renal disease (ESRD) drug market report covering trends, opportunities, strategies, and more

The End Stage Renal Disease (ESRD) Drug Global Market Report 2024 by [The Business Research Company](#) is the most comprehensive report that provides insights on [end stage renal disease \(ESRD\) drug market size](#), end stage renal disease (ESRD) drug market drivers and trends, end stage renal disease (ESRD) drug market major players and end stage renal disease (ESRD) drug market growth across geographies. This report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Drug Delivery Devices Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report>

Drug Device Combination Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drug-device-combination-global-market-report>

Drug Discovery Informatics Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drug-discovery-informatics-global-market-report>

What Does the Business Research Company Do?

The Business Research Company publishes over 15,000 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package, and much more.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/747298413>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.